• Boehringer Ingelheim GmbH, of Ingelheim, Germany, said it started an open-label U.S. expanded access program for investigational oncology compound afatinib, which will be available to eligible patients with locally advanced or metastatic non-small-cell lung cancer who have an epidermal growth factor receptor mutation. Afatinib is an irreversible ErbB family blocker.
To read more on related topics, click on one of the words below.